line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,SMSPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.270089,SMSPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,1452157000.0,SMSPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,SMSPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,343373000.0,SMSPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,5234089000.0,SMSPHARMA.NS
EBITDA,2025-03-31 00:00:00,1452157000.0,SMSPHARMA.NS
EBIT,2025-03-31 00:00:00,1108784000.0,SMSPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-185409000.0,SMSPHARMA.NS
Interest Expense,2025-03-31 00:00:00,185409000.0,SMSPHARMA.NS
Interest Income,2025-03-31 00:00:00,,SMSPHARMA.NS
Normalized Income,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Total Expenses,2025-03-31 00:00:00,6780941000.0,SMSPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,SMSPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,,SMSPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,,SMSPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,,SMSPHARMA.NS
Basic EPS,2025-03-31 00:00:00,,SMSPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,691350000.0,SMSPHARMA.NS
Tax Provision,2025-03-31 00:00:00,249393000.0,SMSPHARMA.NS
Pretax Income,2025-03-31 00:00:00,923375000.0,SMSPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,62244000.0,SMSPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,0.0,SMSPHARMA.NS
Other Special Charges,2025-03-31 00:00:00,,SMSPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-185409000.0,SMSPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,SMSPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,185409000.0,SMSPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,SMSPHARMA.NS
Operating Income,2025-03-31 00:00:00,1046540000.0,SMSPHARMA.NS
Operating Expense,2025-03-31 00:00:00,1546852000.0,SMSPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,402637000.0,SMSPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,343373000.0,SMSPHARMA.NS
Amortization,2025-03-31 00:00:00,,SMSPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,343373000.0,SMSPHARMA.NS
Research And Development,2025-03-31 00:00:00,,SMSPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,SMSPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,SMSPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,SMSPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,SMSPHARMA.NS
Gross Profit,2025-03-31 00:00:00,2593392000.0,SMSPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,5234089000.0,SMSPHARMA.NS
Total Revenue,2025-03-31 00:00:00,7827481000.0,SMSPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,7827481000.0,SMSPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,SMSPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.25575,SMSPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,1210793000.0,SMSPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,SMSPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,315157000.0,SMSPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,4977079000.0,SMSPHARMA.NS
EBITDA,2024-03-31 00:00:00,1210793000.0,SMSPHARMA.NS
EBIT,2024-03-31 00:00:00,895636000.0,SMSPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-234568000.0,SMSPHARMA.NS
Interest Expense,2024-03-31 00:00:00,234568000.0,SMSPHARMA.NS
Interest Income,2024-03-31 00:00:00,7579000.0,SMSPHARMA.NS
Normalized Income,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Total Expenses,2024-03-31 00:00:00,6241595000.0,SMSPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,717000.0,SMSPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,84594228.0,SMSPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,84594228.0,SMSPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,5.89,SMSPHARMA.NS
Basic EPS,2024-03-31 00:00:00,5.89,SMSPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,498260000.0,SMSPHARMA.NS
Tax Provision,2024-03-31 00:00:00,169068000.0,SMSPHARMA.NS
Pretax Income,2024-03-31 00:00:00,661068000.0,SMSPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,44597000.0,SMSPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,0.0,SMSPHARMA.NS
Other Special Charges,2024-03-31 00:00:00,-372000.0,SMSPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-234568000.0,SMSPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,9780000.0,SMSPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,234568000.0,SMSPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,7579000.0,SMSPHARMA.NS
Operating Income,2024-03-31 00:00:00,851039000.0,SMSPHARMA.NS
Operating Expense,2024-03-31 00:00:00,1264516000.0,SMSPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,307862000.0,SMSPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,315157000.0,SMSPHARMA.NS
Amortization,2024-03-31 00:00:00,9116000.0,SMSPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,315157000.0,SMSPHARMA.NS
Research And Development,2024-03-31 00:00:00,111131000.0,SMSPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,142059000.0,SMSPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,47317000.0,SMSPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,94742000.0,SMSPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,717000.0,SMSPHARMA.NS
Gross Profit,2024-03-31 00:00:00,2115555000.0,SMSPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,4977079000.0,SMSPHARMA.NS
Total Revenue,2024-03-31 00:00:00,7092634000.0,SMSPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,7092634000.0,SMSPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-148989.549644,SMSPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.273878,SMSPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,585233000.0,SMSPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,-544000.0,SMSPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-544000.0,SMSPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,321254000.0,SMSPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,3906077000.0,SMSPHARMA.NS
EBITDA,2023-03-31 00:00:00,584689000.0,SMSPHARMA.NS
EBIT,2023-03-31 00:00:00,263435000.0,SMSPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,-211994000.0,SMSPHARMA.NS
Interest Expense,2023-03-31 00:00:00,209944000.0,SMSPHARMA.NS
Interest Income,2023-03-31 00:00:00,7748000.0,SMSPHARMA.NS
Normalized Income,2023-03-31 00:00:00,-70197989.549644,SMSPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Total Expenses,2023-03-31 00:00:00,4972654000.0,SMSPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,804000.0,SMSPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,-0.83,SMSPHARMA.NS
Basic EPS,2023-03-31 00:00:00,-0.83,SMSPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,-70593000.0,SMSPHARMA.NS
Tax Provision,2023-03-31 00:00:00,14650000.0,SMSPHARMA.NS
Pretax Income,2023-03-31 00:00:00,53491000.0,SMSPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,2166000.0,SMSPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,-544000.0,SMSPHARMA.NS
Other Special Charges,2023-03-31 00:00:00,544000.0,SMSPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-211994000.0,SMSPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,9798000.0,SMSPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,209944000.0,SMSPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,7748000.0,SMSPHARMA.NS
Operating Income,2023-03-31 00:00:00,224814000.0,SMSPHARMA.NS
Operating Expense,2023-03-31 00:00:00,1066577000.0,SMSPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,46931000.0,SMSPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,321254000.0,SMSPHARMA.NS
Amortization,2023-03-31 00:00:00,7087000.0,SMSPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,314167000.0,SMSPHARMA.NS
Research And Development,2023-03-31 00:00:00,89192000.0,SMSPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,93206000.0,SMSPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,38227000.0,SMSPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,54979000.0,SMSPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,804000.0,SMSPHARMA.NS
Gross Profit,2023-03-31 00:00:00,1291391000.0,SMSPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,3906077000.0,SMSPHARMA.NS
Total Revenue,2023-03-31 00:00:00,5197468000.0,SMSPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,5197468000.0,SMSPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-333.922635,SMSPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.009025,SMSPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,1188119000.0,SMSPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,-37000.0,SMSPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-37000.0,SMSPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,321525000.0,SMSPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,3335860000.0,SMSPHARMA.NS
EBITDA,2022-03-31 00:00:00,1188082000.0,SMSPHARMA.NS
EBIT,2022-03-31 00:00:00,866557000.0,SMSPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-186043000.0,SMSPHARMA.NS
Interest Expense,2022-03-31 00:00:00,181566000.0,SMSPHARMA.NS
Interest Income,2022-03-31 00:00:00,5596000.0,SMSPHARMA.NS
Normalized Income,2022-03-31 00:00:00,622235666.077365,SMSPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Total Expenses,2022-03-31 00:00:00,4325468000.0,SMSPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,939000.0,SMSPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,7.35,SMSPHARMA.NS
Basic EPS,2022-03-31 00:00:00,7.35,SMSPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,SMSPHARMA.NS
Net Income,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,622199000.0,SMSPHARMA.NS
Tax Provision,2022-03-31 00:00:00,6182000.0,SMSPHARMA.NS
Pretax Income,2022-03-31 00:00:00,684991000.0,SMSPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,20586000.0,SMSPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,-37000.0,SMSPHARMA.NS
Other Special Charges,2022-03-31 00:00:00,37000.0,SMSPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-186043000.0,SMSPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,10073000.0,SMSPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,181566000.0,SMSPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,5596000.0,SMSPHARMA.NS
Operating Income,2022-03-31 00:00:00,824690000.0,SMSPHARMA.NS
Operating Expense,2022-03-31 00:00:00,989608000.0,SMSPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,45498000.0,SMSPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,321525000.0,SMSPHARMA.NS
Amortization,2022-03-31 00:00:00,7100000.0,SMSPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,314425000.0,SMSPHARMA.NS
Research And Development,2022-03-31 00:00:00,,SMSPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,83685000.0,SMSPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,34209000.0,SMSPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,49476000.0,SMSPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,939000.0,SMSPHARMA.NS
Gross Profit,2022-03-31 00:00:00,1814298000.0,SMSPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,3335860000.0,SMSPHARMA.NS
Total Revenue,2022-03-31 00:00:00,5150158000.0,SMSPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,5150158000.0,SMSPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,SMSPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,SMSPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,SMSPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,SMSPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,SMSPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,SMSPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,SMSPHARMA.NS
EBITDA,2021-03-31 00:00:00,,SMSPHARMA.NS
EBIT,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,SMSPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,SMSPHARMA.NS
Interest Income,2021-03-31 00:00:00,3144000.0,SMSPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,SMSPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,SMSPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,1043000.0,SMSPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,84652000.0,SMSPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,7.39,SMSPHARMA.NS
Basic EPS,2021-03-31 00:00:00,7.39,SMSPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,SMSPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,SMSPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,SMSPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,SMSPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,SMSPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,SMSPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,SMSPHARMA.NS
Other Special Charges,2021-03-31 00:00:00,80000.0,SMSPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,SMSPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,9350000.0,SMSPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,SMSPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,3144000.0,SMSPHARMA.NS
Operating Income,2021-03-31 00:00:00,,SMSPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,SMSPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,,SMSPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,SMSPHARMA.NS
Amortization,2021-03-31 00:00:00,4337000.0,SMSPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,SMSPHARMA.NS
Research And Development,2021-03-31 00:00:00,,SMSPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,91964000.0,SMSPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,50903000.0,SMSPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,41061000.0,SMSPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,1043000.0,SMSPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,SMSPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,SMSPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,SMSPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,SMSPHARMA.NS
